STAT3 and myeloproliferative neoplasm: In addition, the levels of phosphorylation of JAK2 and downstream STAT3/5 factors in primary peripheral blood mononuclear cells from MPN patients carrying the JAK2V617F mutation were also analyzed, and the results indicated significant inhibition by ZT55.